VEGFC and neoplasm: found that while VEGF-C induced meningeal lymphangiogenesis allows for larger anti-tumor T cell response against brain tumors and thus increased survival, when mice were given a CCR7 or a CCL21 blockade in combination with VEGF-C, the resulting disruption in DC migration abolished any survival benefit from the VEGF-C (pro-lymphangiogenesis) therapy (122).